Study Complete
Sponsor ID
20130258
Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis
Study Details
The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501 in adults with moderate to severe rheumatoid arthritis (RA).
Protocol Summary
Primary Outcome Measures
Subject incidence of adverse events and serious adverse events
Timeframe: Up to week 72
Clinically significant changes in laboratory values and vital signs
Timeframe: Up to week 72
Incidence of anti-drug antibodies
Timeframe: Up to week 72
Secondary Outcome Measures
ACR 20 (20% improvement in American College of Rheumatology (ACR) core set measurements at all measured time points)
Timeframe: Up to week 70
Disease Activity Score (DAS) 28-CRP at all timepoints
Timeframe: Up to week 70
Locations
Location
Research Site
Budapest, Budapest, Hungary, 1036
Status
Recruiting
Location
Research Site
Carrollton, TX, United States, 75007
Status
Recruiting
Location
Research Site
Covina, CA, United States, 91723
Status
Recruiting
Location
Research Site
Dallas, TX, United States, 75231
Status
Recruiting
Location
Research Site
Duncansville, PA, United States, 16635
Status
Recruiting
Location
Research Site
Huntsville, AL, United States, 35801
Status
Recruiting
Showing {first} - {last} of {total} Results